Catalyst Pharmaceuticals (NASDAQ:CPRX) Upgraded by Baird R W to “Strong-Buy” Rating

Baird R W upgraded shares of Catalyst Pharmaceuticals (NASDAQ:CPRX) to a strong-buy rating in a research note released on Monday,Zacks.com reports.

Other equities analysts also recently issued reports about the company. HC Wainwright upped their price target on Catalyst Pharmaceuticals from $30.00 to $35.00 and gave the stock a “buy” rating in a research report on Friday, January 10th. Stephens assumed coverage on Catalyst Pharmaceuticals in a research report on Monday, November 18th. They issued an “overweight” rating and a $35.00 target price on the stock. Bank of America reissued a “buy” rating and issued a $30.00 target price on shares of Catalyst Pharmaceuticals in a research report on Thursday, January 9th. StockNews.com downgraded Catalyst Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, January 11th. Finally, Robert W. Baird assumed coverage on Catalyst Pharmaceuticals in a research report on Tuesday. They issued an “outperform” rating and a $28.00 target price on the stock. Nine research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $32.25.

Catalyst Pharmaceuticals Stock Up 2.1 %

Shares of NASDAQ:CPRX opened at $23.09 on Monday. The company has a market capitalization of $2.75 billion, a price-to-earnings ratio of 19.57, a price-to-earnings-growth ratio of 2.25 and a beta of 0.80. Catalyst Pharmaceuticals has a 52 week low of $13.12 and a 52 week high of $24.64. The firm has a 50 day moving average of $22.03 and a 200 day moving average of $20.83.

Insider Buying and Selling

In other Catalyst Pharmaceuticals news, insider Steve Miller sold 50,000 shares of the stock in a transaction dated Tuesday, December 10th. The shares were sold at an average price of $21.93, for a total value of $1,096,500.00. Following the completion of the sale, the insider now owns 686,996 shares in the company, valued at approximately $15,065,822.28. This represents a 6.78 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Gary Ingenito sold 12,000 shares of the stock in a transaction dated Wednesday, November 27th. The shares were sold at an average price of $22.72, for a total transaction of $272,640.00. Following the completion of the sale, the insider now owns 51,391 shares of the company’s stock, valued at approximately $1,167,603.52. The trade was a 18.93 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 79,500 shares of company stock worth $1,754,140 in the last 90 days. Insiders own 11.00% of the company’s stock.

Institutional Trading of Catalyst Pharmaceuticals

A number of hedge funds have recently bought and sold shares of the business. GAMMA Investing LLC increased its holdings in shares of Catalyst Pharmaceuticals by 62.1% during the 3rd quarter. GAMMA Investing LLC now owns 1,778 shares of the biopharmaceutical company’s stock worth $35,000 after buying an additional 681 shares during the last quarter. nVerses Capital LLC acquired a new stake in shares of Catalyst Pharmaceuticals during the 3rd quarter worth approximately $50,000. Larson Financial Group LLC increased its holdings in shares of Catalyst Pharmaceuticals by 27,218.2% during the 3rd quarter. Larson Financial Group LLC now owns 3,005 shares of the biopharmaceutical company’s stock worth $60,000 after buying an additional 2,994 shares during the last quarter. Wilmington Savings Fund Society FSB acquired a new stake in shares of Catalyst Pharmaceuticals during the 4th quarter worth approximately $65,000. Finally, KBC Group NV increased its holdings in shares of Catalyst Pharmaceuticals by 48.8% during the 4th quarter. KBC Group NV now owns 4,699 shares of the biopharmaceutical company’s stock worth $98,000 after buying an additional 1,542 shares during the last quarter. Institutional investors and hedge funds own 79.22% of the company’s stock.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.